Research Analysts Set Expectations for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for CervoMed in a research report issued to clients and investors on Friday, May 15th. Brookline Capital Markets analyst F. Ahmed expects that the company will post earnings per share of ($0.86) for the quarter. The consensus estimate for CervoMed’s current full-year earnings is ($2.31) per share. Brookline Capital Markets also issued estimates for CervoMed’s Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($1.04) EPS, Q4 2026 earnings at ($1.55) EPS and FY2026 earnings at ($4.34) EPS.

Several other equities research analysts have also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CervoMed in a report on Monday, April 20th. Roth Mkm set a $9.00 price objective on CervoMed in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of CervoMed in a research note on Thursday, April 23rd. Chardan Capital lifted their price objective on CervoMed from $15.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $31.00 price objective on shares of CervoMed in a research note on Wednesday, April 22nd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.60.

CervoMed Price Performance

NASDAQ CRVO opened at $3.04 on Tuesday. The company has a market cap of $28.15 million, a PE ratio of -0.93 and a beta of -0.63. The stock’s 50 day simple moving average is $3.97 and its 200-day simple moving average is $5.90. CervoMed has a 1-year low of $2.89 and a 1-year high of $13.13.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Friday, May 15th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.07). CervoMed had a negative return on equity of 116.01% and a negative net margin of 672.80%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new position in CervoMed during the 3rd quarter worth $247,000. AQR Capital Management LLC acquired a new position in CervoMed during the 1st quarter worth $227,000. State Street Corp grew its stake in CervoMed by 11.4% during the 4th quarter. State Street Corp now owns 20,527 shares of the company’s stock worth $162,000 after purchasing an additional 2,100 shares in the last quarter. HRT Financial LP acquired a new position in CervoMed during the 4th quarter worth $113,000. Finally, Jane Street Group LLC acquired a new position in CervoMed during the 4th quarter worth $88,000. 25.15% of the stock is owned by institutional investors and hedge funds.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.